J Minim Invasive Gynecol
October 2024
Study Objective: To investigate perioperative outcomes of minimally invasive higher order myomectomy as defined by removal of 10 or more fibroids.
Design: A retrospective cohort study between January 2018 and December 2022.
Setting: A tertiary academic medical center.
Background: Postoperative pain continues to be an undermanaged part of the surgical experience. Multimodal analgesia has been adopted in response to the opioid epidemic, but opioid prescribing practices remain high after minimally invasive hysterectomy. Novel adjuvant opioid-sparing analgesia to optimize acute postoperative pain control is crucial in preventing chronic pain and minimizing opioid usage.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
January 2023
Objective: To assess the utilization and cost of intraoperative cell salvage (ICS) in minimally invasive myomectomy.
Study Design: Retrospective cohort study of patients who underwent minimally invasive myomectomy at a quaternary care academic hospital. Patients were classified into: ICS setup vs no ICS setup, ICS setup with reinfusion vs ICS setup without reinfusion.
Background And Objectives: To evaluate postoperative opioid use after benign minimally-invasive gynecologic surgery and assess the impact of a patient educational intervention regarding proper opioid use/disposal.
Methods: Educational pamphlets were provided preoperatively. Patients underwent hysterectomy, myomectomy, or other laparoscopic procedures.
IEEE Trans Med Imaging
December 2021
Hysterectomy (i.e., surgical removal of the uterus) requires severing the main blood supply to the uterus (i.
View Article and Find Full Text PDFStudy Objective: To demonstrate different techniques, and detail the considerations for obtaining primary laparoscopic access in gynecologic surgery.
Design: Video demonstration of the techniques with narrated discussion of each method.
Setting: The methods for primary entry in laparoscopy vary by location and technique [1,2].
Ureteral injury is a known complication of minimally invasive gynecologic surgery. Despite being discussed preoperatively and included in consent forms, litigations that involve such injury continue to be prevalent. Our aim was to review all major litigations involving ureteral injuries related to minimally invasive gynecologic surgery to determine the most common allegations from plaintiffs and highlight factors that aided defendants.
View Article and Find Full Text PDFObjective: To examine mammographic density before and after at least 1 year of vaginal estrogen use in a small cohort of healthy postmenopausal women and women with a personal history of breast cancer.
Methods: We extracted data via chart review of patients from a single practitioner's menopause specialty clinic in Baltimore, MD. Mammographic change was primarily determined via the Bi-RADS scoring system, including the Bi-RADS density score.
Semin Reprod Med
November 2017
Objective: To assess geographical distribution and practice characteristics of fertility clinics inclusive of lesbian, gay, bisexual, and transgender (LGBT) patients.
Design: Cross-sectional analysis.
Setting: Not applicable.
Purpose: To identify trends regarding therapeutic approaches to metformin administration in patients undergoing in vitro fertilization (IVF) treatment worldwide.
Methods: A retrospective evaluation utilizing the results of a web-based survey, IVFWorldwide ( www.IVF-worldwide.
Background: In 2010, the Clinical and Laboratory Standards Institute (CLSI) revised and lowered the ceftriaxone minimum inhibitory concentration breakpoints for Enterobacteriaceae and removed the requisite extended spectrum β-lactamase phenotypic testing for organisms with elevated minimum inhibitory concentrations. The impact that these recommendations have on clinical outcomes of children have not been previously evaluated.
Methods: We conducted a retrospective study to compare clinical outcomes between children treated with ceftriaxone and those treated with broader spectrum β-lactams for Enterobacteriaceae bacteremia with reduced susceptibility (minimum inhibitory concentrations 4-8 µg/mL) to ceftriaxone according to the new CLSI interpretive criteria.